Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Accounts Payables (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Accounts Payables for 10 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 336.44% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 336.44% year-over-year, with the annual reading at $4.0 million for FY2025, 336.44% up from the prior year.
  • Accounts Payables for Q4 2025 was $4.0 million at Rein Therapeutics, down from $4.1 million in the prior quarter.
  • The five-year high for Accounts Payables was $6.0 million in Q2 2025, with the low at $136000.0 in Q2 2023.
  • Average Accounts Payables over 5 years is $1.6 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Accounts Payables plummeted 92.19% in 2023, then skyrocketed 670.84% in 2025.
  • Over 5 years, Accounts Payables stood at $1.2 million in 2021, then surged by 42.15% to $1.7 million in 2022, then tumbled by 30.81% to $1.2 million in 2023, then decreased by 23.45% to $911000.0 in 2024, then surged by 336.44% to $4.0 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $4.0 million, $4.1 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.